Abhirami Kannan Iyer

Abhirami Kannan Iyer

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
MMMiguel A. Minaya
Miguel A. Minaya
SMSidhartha Mahali
Sidhartha Mahali
AIAbhirami Kannan Iyer
Abhirami Kannan Iyer
AEAbdallah M. Eteleeb
Abdallah M. Eteleeb
RMRita Martinez
Rita Martinez
CKCeleste M. Karch
Celeste M. Karch
Introduction: More than 50 mutations in the MAPT gene result in heterogeneous forms of frontotemporal lobar dementia with tau inclusions (FTLD-Tau). However, early pathogenic events that lead to disease and the degree to which they are common across MAPT mutations remain poorly understood. The goal of this study is to determine whether there is a common molecular signature of FTLD-Tau.Methods: We analyzed genes differentially expressed in induced pluripotent stem cell–derived neurons (iPSC-neurons) that represent the three major categories of MAPT mutations: splicing (IVS10 + 16), exon 10 (p.P301L), and C-terminal (p.R406W) compared with isogenic controls. The genes that were commonly differentially expressed in MAPT IVS10 + 16, p.P301L, and p.R406W neurons were enriched in trans-synaptic signaling, neuronal processes, and lysosomal function. Many of these pathways are sensitive to disruptions in calcium homeostasis. One gene, CALB1, was significantly reduced across the three MAPT mutant iPSC-neurons and in a mouse model of tau accumulation. We observed a significant reduction in calcium levels in MAPT mutant neurons compared with isogenic controls, pointing to a functional consequence of this disrupted gene expression. Finally, a subset of genes commonly differentially expressed across MAPT mutations were also dysregulated in brains from MAPT mutation carriers and to a lesser extent in brains from sporadic Alzheimer disease and progressive supranuclear palsy, suggesting that molecular signatures relevant to genetic and sporadic forms of tauopathy are captured in a dish. The results from this study demonstrate that iPSC-neurons capture molecular processes that occur in human brains and can be used to pinpoint common molecular pathways involving synaptic and lysosomal function and neuronal development, which may be regulated by disruptions in calcium homeostasis.

30 July 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
RARicardo D’OLiveira Albanus
Ricardo D’OLiveira Albanus
GFGina M. Finan
Gina M. Finan
LBLogan Brase
Logan Brase
NSNicholas Sweeney
Nicholas Sweeney
TKTae Yeon Kim
Tae Yeon Kim
TKTae-Wan Kim
Tae-Wan Kim
Cellular cross-talk, mediated by membrane receptors and their ligands, is crucial for brain homeostasis and can contribute to neurodegenerative diseases such as Alzheimer’s disease (AD). To find cross-talk dysregulations involved in AD, we reconstructed cross-talk networks from single-nucleus transcriptional profiles of 67 clinically and neuropathologically well-characterized controls and AD brain donors from the Knight Alzheimer Disease Research Center and the Dominantly Inherited Alzheimer Network cohorts. We predicted a role for TREM2 and additional AD risk genes mediating neuron-microglia cross-talk in AD. We identified a gene network mediating neuron-microglia cross-talk through TREM2 and neuronal SEMA6D, which we predicted is disrupted in late AD stages. Using spatial transcriptomics on the human brain, we observed that the SEMA6D-TREM2 cross-talk gene network is activated near Aβ plaques and SEMA6D-expressing cells. Using tissue immunostaining of human brains, we found that SEMA6D colocalizes with Aβ plaques and TREM2-activated microglia. In addition, we found that plaque-proximal SEMA6D abundance decreased with the disease stage, which correlated with a reduction in microglial activation near plaques. These findings suggest that the loss of SEMA6D signaling impairs microglial activation and Αβ clearance. To validate this hypothesis, we leveraged TREM2 knockout human induced pluripotent stem cell–derived microglia and observed that SEMA6D induces microglial activation and Aβ plaque phagocytosis in a TREM2-dependent manner. In summary, we demonstrate that characterizing cellular cross-talk networks can yield insights into AD biology, provide additional context to understand AD genetic risk, and find previously unknown therapeutic targets and pathways.

17 June 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AIAbhirami Kannan Iyer
Abhirami Kannan Iyer
LVLisa Vermunt
Lisa Vermunt
FMFarzaneh S. Mirfakhar
Farzaneh S. Mirfakhar
MMMiguel Minaya
Miguel Minaya
MAMariana Acquarone
Mariana Acquarone
CKCeleste M. Karch
Celeste M. Karch
Neuronal dysfunction has been extensively studied as a central feature of neurodegenerative tauopathies. However, across neurodegenerative diseases, there is strong evidence for active involvement of immune cells like microglia in driving disease pathophysiology. Here, we demonstrate that MAPT mRNA and tau protein are expressed in microglia in human brains and in human induced pluripotent stem cell (iPSC)-derived microglia like cells (iMGLs). Using iMGLs harboring the MAPT IVS10 + 16 mutation and isogenic controls, we demonstrate that a tau mutation is sufficient to alter microglial transcriptional states. We discovered that MAPT IVS10 + 16 microglia exhibit cytoskeletal abnormalities, stalled phagocytosis, disrupted TREM2/TYROBP networks, and altered metabolism. Additionally, we found that secretory factors from MAPT IVS10 + 16 iMGLs impact neuronal health, reducing synaptic density in neurons. Key features observed in vitro were recapitulated in human brain tissue and cerebrospinal fluid from MAPT mutations carriers. Together, our findings that MAPT IVS10 + 16 drives cell-intrinsic dysfunction in microglia that impacts neuronal health has major implications for development of therapeutics for tauopathies.

21 September 2015 in Immunology
Verified
Journal Article
Closed access
PDF file
AIAbhirami Kannan Iyer
Abhirami Kannan Iyer
JLJianyun Liu
Jianyun Liu
RGRichard M. Gallo
Richard M. Gallo
MKMark H. Kaplan
Mark H. Kaplan
RBRandy R. Brutkiewicz
Randy R. Brutkiewicz

Verified
Journal Article
Open access
PDF file
AIAbhirami Kannan Iyer
Abhirami Kannan Iyer
KJKathryn J. Jones
Kathryn J. Jones
VSVirginia M. Sanders
Virginia M. Sanders
Chandler WalkerChandler Walker
Chandler Walker
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive loss of lower and upper motor neurons (MN) leading to muscle weakness, paralysis and eventually death. Although a highly varied etiology results in ALS, it broadly manifests itself as sporadic and familial forms that have evident similarities in clinical symptoms and disease progression. There is a tremendous amount of knowledge on molecular mechanisms leading to loss of MNs and neuromuscular junctions (NMJ) as major determinants of disease onset, severity and progression in ALS. Specifically, two main opposing hypotheses, the dying forward and dying back phenomena, exist to account for NMJ denervation. The former hypothesis proposes that the earliest degeneration occurs at the central MNs and proceeds to the NMJ, whereas in the latter, the peripheral NMJ is the site of precipitating degeneration progressing backwards to the MN cell body. A large body of literature strongly indicates a role for the immune system in disease onset and progression via regulatory involvement at the level of both the central and peripheral nervous systems (CNS and PNS). In this review, we discuss the earliest reported immune responses with an emphasis on newly identified immune players in mutant superoxide dismutase 1 (mSOD1) transgenic mice, the gold standard mouse model for ALS.

22 November 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JLJianyun Liu
Jianyun Liu
RGRichard M. Gallo
Richard M. Gallo
Masood A KhanMasood A Khan
Masood A Khan
AIAbhirami Kannan Iyer
Abhirami Kannan Iyer
IKIan M. Kratzke
Ian M. Kratzke
RBRandy R. Brutkiewicz
Randy R. Brutkiewicz